Castle Biosciences (CSTL) Cost of Revenue (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Cost of Revenue data on file, last reported at $20.5 million in Q1 2026.

• Quarterly Cost of Revenue rose 25.33% year-over-year to $20.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75.2 million (up 19.91% YoY) and the FY2025 annual result came in at $71.0 million, up 17.98% from the prior year.
• Cost of Revenue grew to $20.5 million in Q1 2026 per CSTL's latest filing, from $18.3 million in the prior quarter.
• The five-year high for Cost of Revenue was $20.5 million in Q1 2026, with the low at $5.9 million in Q1 2022.
• Average Cost of Revenue over 5 years is $13.5 million, with a median of $13.9 million recorded in 2024.
• Year-over-year, Cost of Revenue soared 107.9% in 2022 and advanced 13.17% in 2025.
• Castle Biosciences' Cost of Revenue stood at $9.5 million in 2022, then surged by 30.49% to $12.4 million in 2023, then jumped by 30.27% to $16.2 million in 2024, then grew by 13.17% to $18.3 million in 2025, then grew by 12.11% to $20.5 million in 2026.
• Business Quant data shows CSTL's Cost of Revenue at $20.5 million in Q1 2026, $18.3 million in Q4 2025, and $18.7 million in Q3 2025.